1. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol. 2005; 23:1782–1790.
Article
2. Wan C, Du J, Fang H, Li F, Wang L. Evaluation of breast lesions by contrast enhanced ultrasound: qualitative and quantitative analysis.Eur J Radiol. 2012; 81:e444–e450.
3. Tuncbilek N, Unlu E, Karakas HM, Cakir B, Ozyilmaz F. Evaluation of tumor angiogenesis with contrast-enhanced dynamic magnetic resonance mammography. Breast J. 2003; 9:403–408.
Article
4. Schroeder RJ, Bostanjoglo M, Rademaker J, Maeurer J, Felix R. Role of power Doppler techniques and ultrasound contrast enhancement in the differential diagnosis of focal breast lesions.Eur Rad/iiol. 2003; 13:68–79.
5. Xiao X, Ou B, Yang H, Wu H, Luo B. Breast contrast-enhanced ultrasound: is a scoring system feasible? A preliminary study in China. PLoS One. 2014; 9:e105517.
Article
6. Li K, Su ZZ, Xu EJ, Ju JX, Meng XC, Zheng RQ. Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma. BMC Cancer. 2016; 16:277.
Article
7. Wang YM, Fan W, Zhang K, Zhang L, Tan Z, Ma R. Comparison of transducers with different frequencies in breast contrast-enhanced ultrasound (CEUS) using SonoVue as contrast agent. Br J Radiol. 2016; 89:20151050.
Article
8. Ricci P, Cantisani V, Ballesio L, Pagliara E, Sallusti E, Drudi FM, et al. Benign and malignant breast lesions: efficacy of real time contrast-enhanced ultrasound vs. magnetic resonance imaging. Ultraschall Med. 2007; 28:57–62.
Article
9. Zhao H, Xu R, Ouyang Q, Chen L, Dong B, Huihua Y. Contrast-enhanced ultrasound is helpful in the differentiation of malignant and benign breast lesions.Eur J Radiol. 2010; 73:288–293.
10. Hu Q, Wang XY, Zhu SY, Kang LK, Xiao YJ, Zheng HY. Meta-analysis of contrast-enhanced ultrasound for the differentiation of benign and malignant breast lesions.Acta Radiol. 2015; 56:25–33.
11. Wan CF, Du J, Fang H, Li FH, Zhu JS, Liu Q. Enhancement patterns and parameters of breast cancers at contrast-enhanced US: correlation with prognostic factors. Radiology. 2012; 262:450–459.
Article
12. Liu H, Jiang Y, Dai Q, Zhu Q, Wang L, Lu J. Peripheral enhancement of breast cancers on contrast-enhanced ultrasound: correlation with microvessel density and vascular endothelial growth factor expression.Ultrasound Med Biol. 2014; 40:293–299.
13. Ji CL, Li XL, He YP, Li DD, Gu XG, Xu HX. Quantitative parameters of contrast-enhanced ultrasound in breast invasive ductal carcinoma: the correlation with pathological prognostic factors.Clin Hemorheol Microcirc. 2017; 66:333–345.
14. Nakata N, Ohta T, Nishioka M, Takeyama H, Toriumi Y, Kato K, et al. Optimization of region of interest drawing for quantitative analysis: differentiation between benign and malignant breast lesions on contrast-enhanced sonography. J Ultrasound Med. 2015; 34:1969–1976.
15. Masumoto N, Kadoya T, Amioka A, Kajitani K, Shigematsu H, Emi A, et al. Evaluation of malignancy grade of breast cancer using perflubutane-enhanced ultrasonography. Ultrasound Med Biol. 2016; 42:1049–1057.
Article
16. Zhao YX, Liu S, Hu YB, Ge YY, Lv DM. Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: a retrospective study.Onco Targets Ther. 2017; 10:1123–1129.
17. Kim Y, Kim SH, Song BJ, Kang BJ, Yim KI, Lee A, et al. Early prediction of response to neoadjuvant chemotherapy using dynamic contrast-enhanced MRI and ultrasound in breast cancer.Korean J Radiol. 2018; 19:682–691.
18. Sinha S, Sinha N, Bandyopadhyay R, Mondal SK. Robinson's cytological grading on aspirates of breast carcinoma: correlation with Bloom Richardson's histological grading.J Cytol. 2009; 26:140–143.
19. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, et al. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol. 2014; 25:1004–1011.
Article
20. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012; 30:729–734.
Article
21. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Cl/iin Oncol. 2013; 31:3997–4013.
Article
22. Penault-Llorca F, André F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.J Clin Oncol. 2009; 27:2809–2815.
23. Li X, Li Y, Zhu Y, Fu L, Liu P. Association between enhancement patterns and parameters of contrast-enhanced ultrasound and microvessel distribution in breast cancer. Oncol Lett. 2018; 15:5643–5649.
Article
24. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2005; 18:26–35.
Article
25. Zhao LX, Liu H, Wei Q, Xu G, Wu J, Xu HX, et al. Contrast-enhanced ultrasonography features of breast malignancies with different sizes: correlation with prognostic factors.BioMed Res Int. 2015; 2015:613831.
26. Koukourakis MI, Manolas C, Minopoulos G, Giatromanolaki A, Sivridis E. Angiogenesis relates to estrogen receptor negativity, c-erbB-2 overexpression and early relapse in node-negative ductal carcinoma of the breast. Int J Surg Pathol. 2003; 11:29–34.
Article
27. Du J, Li FH, Fang H, Xia JG, Zhu CX. Microvascular architecture of breast lesions: evaluation with contrast-enhanced ultrasonographic micro flow imaging. J Ultrasound Med. 2008; 27:833–842. ; quiz 844.
28. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer.Mod Pathol. 2008; 21(Suppl 2):S8–S15.
29. Metz S, Daldrup-Unk HE, Richter T, Räth C, Ebert W, Settles M, et al. Detection and quantification of breast tumor necrosis with MR imaging: value of the necrosis-avid contrast agent Gadophrin-3.Acad Radiol. 2003; 10:484–490.
30. Poteca˘ T, Coma˘nescu M, Poteca˘ A, Cocosila C. The many faces of triple negative breast cancer.Chirurgia (Bucur). 2014; 109:471–479.
31. Jiang YX, Liu H, Liu JB, Zhu QL, Sun Q, Chang XY. Breast tumor size assessment: comparison of conventional ultrasound and contrast-enhanced ultrasound.Ultrasound Med Biol. 2007; 33:1873–1881.